title: The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
abstract: BACKGROUND
  The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI.
  
  
  METHODS
  Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (> or = 840 pmol/L, n = 65) and low MPO group (< 840 pmol/L, n = 124).
  
  
  RESULTS
  The high MPO group had significantly more frequent anterior wall infarctions (p < 0.001) and Killip class > 1 on admission (p = 0.013) as well as lower left ventricular ejection fraction (LVEF) (p = 0.011) and higher B-type natriuretic peptide (BNP) (p = 0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high MPO group (13.8%) than in the low MPO group (1.6%) (p = 0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95% CI 1.13 - 13.34, p = 0.031).
  
  
  CONCLUSIONS
  Plasma MPO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI.
authors.affiliation: Center for Medical Biochemistry, School of Pharmacy, University ofBelgrade, Clinical Center of Serbia, Belgrade, Serbia. sanjast@eunet.rs
authors.forename: Sanja
authors.initials: S
authors.lastname: Stankovic
authors.forename: Milika
authors.initials: M
authors.lastname: Asanin
authors.forename: Nada
authors.initials: N
authors.lastname: Majkic-Singh
authors.forename: Svetlana
authors.initials: S
authors.lastname: Ignjatovic
authors.forename: Mirjana
authors.initials: M
authors.lastname: Mihailovic
authors.forename: Ivica
authors.initials: I
authors.lastname: Nikolajevic
authors.forename: Igor
authors.initials: I
authors.lastname: Mrdovic
authors.forename: Dragan
authors.initials: D
authors.lastname: Matic
authors.forename: Lidija
authors.initials: L
authors.lastname: Savic
authors.forename: Jelena
authors.initials: J
authors.lastname: Marinkovic
authors.forename: Miodrag
authors.initials: M
authors.lastname: Ostojic
authors.forename: Zorana
authors.initials: Z
authors.lastname: Vasiljevic
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001145:Arrhythmias, Cardiac / Q000201:enzymology* / Q000401:mortality / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000201:enzymology* / Q000401:mortality / Q000503:physiopathology; D009195:Peroxidase / Q000097:blood*; D011237:Predictive Value of Tests; D012372:ROC Curve; D055771:Serbia / Q000453:epidemiology; D015996:Survival Rate
chemical_list: D015415:Biomarkers; D009195:Peroxidase